Piramal Pharma Receives 68.5 ESG Rating for FY25 from SES ESG

Piramal Pharma Limited has achieved an Environmental, Social, and Governance (ESG) rating of 68.5 for the Fiscal Year 2024-25. The rating was provided by SES ESG Research Pvt. Ltd.

Rating Details

Piramal Pharma Limited (PPL) has been assigned an ESG rating of 68.5 for Fiscal Year 2024-25 by SES ESG Research Pvt. Ltd. Crucially, the rating was voluntarily prepared by SES ESG based on data available in the public domain. Piramal Pharma Limited itself did not engage SES ESG for this assessment, meaning the company had no direct input into the methodology or data selection for this specific rating. This independently generated score offers a snapshot of the company's ESG performance according to SES ESG's evaluation criteria.

Why the Rating Matters

ESG ratings are increasingly significant for institutional investors, influencing capital allocation and corporate valuations. While this rating is based on public data and was not company-initiated, it still provides an external perspective on Piramal Pharma's sustainability efforts. For investors looking at long-term value creation and responsible business practices, such ratings offer a benchmark, even when prepared independently by the rating agency.

Piramal Pharma's ESG Background and Previous Ratings

Piramal Pharma has demonstrated a commitment to sustainability, guided by its purpose 'Doing Well and Doing Good'. The company regularly publishes sustainability reports, outlining its ESG framework built on four core pillars: Business Resilience, Quality & Excellence, Responsible Operations, and Stakeholder Centricity. Through the Piramal Foundation, the company actively pursues Corporate Social Responsibility (CSR) initiatives focusing on health, education, and community well-being across India.

PPL's ESG efforts have also been recognized by other evaluators. For the 2025 S&P Global Corporate Sustainability Assessment (CSA), the company scored 63, a 15% year-over-year improvement that placed it in the 91st percentile of the pharmaceutical industry. Additionally, for FY2023-24, Piramal Pharma received an ESG rating of 61 from NSE Sustainability.

Implications for Investors and Disclosure

The voluntary rating highlights the growing importance of publicly accessible ESG data for external assessments. Investors may consider this score as one reference point when evaluating Piramal Pharma's sustainability profile, alongside other ratings. The rating also offers a data point for comparing Piramal Pharma's ESG standing within the Indian pharmaceutical sector. This reinforces the need for companies to maintain robust and transparent ESG information publicly.

Potential Limitations

As the rating was voluntarily prepared by SES ESG based on public data, Piramal Pharma had no direct input into the methodology or data used. This lack of direct engagement could mean the rating does not fully capture the company's nuanced ESG initiatives or might reflect only what is easily observable externally.

Peer Comparison in the Sector

In general, the Indian pharmaceutical sector lags behind its global peers in ESG practices, facing challenges in regulatory consistency, awareness, and resources. A recent analysis indicated that Indian pharma companies have 'Emerging' ESG maturity, with composite ESG Opportunity scores around 40. Piramal Pharma's score of 68.5 from SES ESG appears to position it ahead of this sector-wide emerging average, though direct peer ratings for the same period from SES ESG are not readily available.

Future Tracking Points

Future engagement with SES ESG or other rating agencies will be noteworthy, potentially influencing methodology and data used. The company's efforts to improve transparency and comprehensiveness of its publicly available ESG disclosures are also key. Monitoring broader ESG trends and ratings across the Indian pharmaceutical industry will be important. Investor and analyst commentary on how this rating is interpreted alongside other ESG disclosures will be watched. Finally, tracking progress of PPL's strategic ESG initiatives, including decarbonization and CSR activities, remains relevant.